Study of VIR-2218 + VIR-3434 in Subjects With Chronic Hepatitis B Virus Infection

• Status: Recruiting
• Trial end date: 2025-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218+ VIR-3434 and will be assessed for safety, tolerability, and efficacy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vir Biotechnology, Inc.

Criteria

Inclusion Criteria:

• Male or female ages 18 - <66 years

• Chronic HBV infection for >/= 6 months

• On NRTI therapy for >/= 2 months at the time of screening

Exclusion Criteria:

• Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation

• Significant fibrosis or cirrhosis

• History or evidence of drug or alcohol abuse

• History of chronic liver disease from any cause other than chronic HBV infection

• History of hepatic decompensation

• History of anaphylaxis

• History of allergic reactions to monoclonal antibodies or antibody fragments

• History of immune complex disease

• Active infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis Delta virus (HDV)